Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Liberty Drug & Surgical
483
•Liberty Drug & Surgical•May 22, 2015

Liberty Drug & Surgical – FDA 483, May 22, 2015

Record Details

The FDA Form 483 details numerous deficiencies observed during an inspection of a drug manufacturing facility. The facility's design and operations are not preventing contamination. Raw materials, including non-sterile IV bags and containers, are handled in an uncontrolled pharmacy area, wiped with non-sterile materials, and transferred into ISO 7 and ISO 6 clean rooms without adequate sanitization. A non-sterile swab was used on IV bag ports in an ISO 5 laminar flow hood.

Procedures to prevent microbiological contamination are not established or followed; for instance, an IV bag that fell on the floor was still used for a patient prescription. The ISO 7 Anteroom is undersized and contains a sink with a non-potable water source.

Aseptic processing areas lack proper systems for maintaining equipment and monitoring environmental conditions. Smoke studies are not performed under dynamic conditions. Routine environmental monitoring (viable air, non-viable air, surface contact plates) is not conducted, with an outside lab performing it only quarterly. Viable and non-viable air monitoring is absent in the ISO 5 laminar flow hood, and personnel fingertip monitoring is not routine.

Personnel gowning is inappropriate, consisting of non-sterile lab coats, and sterile glove donning was observed to compromise sterility. Cleaning and disinfecting procedures are deficient, with non-sterile wipes stored improperly.

The stability program is inadequate; beyond-use dates for Doxycycline and 17-Hydroxyprogesterone were established without

Company
Liberty Drug & Surgical
Inspection date
May 22, 2015
Product type
Drugs
Office
New Jersey District Office
People
  • Barbara Wilimczyk-Macri (Senior Compliance Officer)
  • Philip I. Stefanos (Equity Research Director)
  • Susan T. Hadman (Microbiologist)
  • Frederick Razzaghi (Advisor)
  • Nicholas A. Violand (Director, Enterprise Regulatory Compliance)
View Company Profile

ID · 8a7a06be-aa00-4a13-ad58-9415287f3465

Violation Codes2
21 CFR 21021 CFR 211

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Liberty Drug & Surgical
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.